About

BayhDole25 is a not-for-profit educational and research organization created to study the U.S. Bayh-Dole Act of 1980, as well as similar U.S. and international technology transfer legislation and related issues. BayhDole25 performs independent, non-partisan research projects and provides educational materials relating to technology transfer legislation and its role in the successful commercialization of science and technology through public-private partnership. BayhDole25 intends to improve the general understanding of the economic and social impact of technology transfer legislation in the United States and abroad that were inspired by the Bayh-Dole Act. BayhDole25 has a pending application for 501(C)(3) status.

Provide a focal point to gather together educational resources encompassing the wide impact of the first quarter-century of experience under the Bayh Dole Act of 1980 -- along with related U.S. technology transfer laws -- which served as a catalyst for American innovation, launched the biotechnology revolution and provided ongoing social, economic and other benefits for patients and for society as a whole;

The success of the Bayh-Dole framework rests on three pillars: a recognition of the importance of market forces (and market-oriented pricing) to spur economic growth and development of biotechnology; strong rule-of-law protection for intellectual property (patents, data exclusivity, copyright, & trademarks, etc.), and a durable government commitment to education and financing of scientific research in universities and institutions.

The Bayh-Dole Act has served “as a catalyst for increasing the social and economic benefits from public research funding”, according to the OECD, and has been adopted as a model by OECD and developing countries alike. Countries that seek to compete in high-technology industries—especially biotechnology—realize that efficient use of both public and private resources is necessary to achieve their ends, and to retain at home the best and brightest of their scientists and entrepreneurs.

Susan Finston. Susan launched Finston Consulting, LLC in June, 2005. She is also the founding Executive Director of the American BioIndustry Alliance (ABIA), a new advocacy organization that seeks enabling conditions for biotechnology through sustainable, mutually beneficial Access and Benefit Sharing (ABS) policies, including technology transfer policies aligned with the principles of the Bayh Dole Act. Her previous experience includes 5 1/2 years at the Pharmaceutical Research and Manufacturers of America (PhRMA), where she was Associate Vice President for Intellectual Property, Middle East/Africa and South Asian Affairs and 11 years in the U.S. Foreign Service where she specialized in intellectual property, trade and development issues. Susan graduated from the University of Michigan, Ann Arbor, with a joint J.D./M.P.P. degree and holds a B.S. in Philosophy from the University of Michigan Honors College. She lives in Washington, D.C .

Interested in being a part? Want to support the cause? Just want to know more? Contact us. We're eager to hear from you.